Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 5/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | FBP1 | P09467 | 1/20 | 0.53 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.52 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.52 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.52 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.52 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13874966 | 0.91 | NFE2L2 (0.84) | NFE2L2HTTFBP1CHRNB2CHRNB4 | |
| SCHEMBL13790316 | 0.91 | NFE2L2 (0.82) | NFE2L2FBP1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL3904046 | 0.85 | NFE2L2 (0.73) | NFE2L2FBP1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL5496405 | 0.85 | NFE2L2 (0.73) | NFE2L2FBP1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL15623938 | 0.84 | NFE2L2 (0.72) | NFE2L2FBP1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL14363044 | 0.83 | NFE2L2 (0.71) | NFE2L2HTT | |
| SCHEMBL22398153 | 0.82 | NFE2L2 (0.70) | NFE2L2FBP1 | |
| SCHEMBL22398154 | 0.82 | NFE2L2 (0.70) | NFE2L2FBP1 | |
| SCHEMBL30632949 | 0.82 | NFE2L2 (0.70) | NFE2L2FBP1 | |
| SCHEMBL8139857 | 0.82 | NFE2L2 (0.70) | NFE2L2FBP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3116851-B1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | SALK INST FOR BIOLOGICAL STUDI (US) | 2023-07-26 | — | — | EP | disclosed |
| US-20220023172-A1 | COSMETIC COMPOSITIONS AND METHODS OF USE | TRUJILLO KRISTINA (US) | 2022-01-27 | — | — | US | disclosed |
| US-20200397676-A1 | COSMETIC COMPOSITIONS AND METHODS OF USE | K&K BIOTECH (US) | 2020-12-24 | — | — | US | disclosed |
| WO-2020112998-A1 | COSMETIC COMPOSITIONS AND METHODS OF USE | STC.UNM (US) | 2020-06-04 | — | — | WO | disclosed |
| US-20190160021-A1 | Substituted Stilbenes as Inhibitors of NF-kappaB and Activators of Nrf2 | STC UNM (US) | 2019-05-30 | — | — | US | disclosed |
| WO-2017078927-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2017-05-11 | — | — | WO | disclosed |
| US-20170066724-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2017-03-09 | — | — | US | disclosed |
| WO-2015138969-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2015-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066724-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | FXR2, FXR1, SLC10A2 | NFE2L2 375/4885HTT 3781/4885FBP1 30/4885 |
| US-20190160021-A1 | Substituted Stilbenes as Inhibitors of NF-kappaB and Activators of Nrf2 | NFKBIA, NFE2L2, NFKB2 | NFE2L2 2/4885HTT 310/4885FBP1 2897/4885 |
| US-20220023172-A1 | COSMETIC COMPOSITIONS AND METHODS OF USE | NFKBIA, IKBKB, NFKB2 | NFE2L2 9/4885HTT 3472/4885FBP1 3048/4885 |
| US-20200397676-A1 | COSMETIC COMPOSITIONS AND METHODS OF USE | KEAP1, NFE2L2, NQO1 | NFE2L2 2/4885HTT 3460/4885FBP1 2440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.